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Abstract
To survive proteotoxic stress, cancer cells activate the proteotoxic-stress response pathway, which is controlled by the
transcription factor heat shock factor 1 (HSF1). This pathway supports cancer initiation, cancer progression and
chemoresistance and thus is an attractive therapeutic target. As developing inhibitors against transcriptional regulators, such
as HSF1 is challenging, the identification and targeting of upstream regulators of HSF1 present a tractable alternative
strategy. Here we demonstrate that in triple-negative breast cancer (TNBC) cells, the dual specificity tyrosine-regulated
kinase 2 (DYRK2) phosphorylates HSF1, promoting its nuclear stability and transcriptional activity. DYRK2 depletion
reduces HSF1 activity and sensitises TNBC cells to proteotoxic stress. Importantly, in tumours from TNBC patients,
DYRK2 levels positively correlate with active HSF1 and associates with poor prognosis, suggesting that DYRK2 could be
promoting TNBC. These findings identify DYRK2 as a key modulator of the HSF1 transcriptional programme and a
potential therapeutic target.
Introduction
Approximately 90% of solid tumours and 75% of hemato-
poietic cancers exhibit some degree of aneuploidy [1].
Evidence from yeast and mammalian systems has shown
that aneuploid cells are less fit than their euploid counter-
parts [2, 3]. This is believed to be due to gene dosage
imbalances, which cause the accumulation of excess and
often misfolded proteins that must be chaperoned and/or
degraded in order to prevent proteotoxic stress [4, 5].
To survive these aneuploidy-related imbalances, cells
engage protein degradation and folding pathways [6, 7], and
one might predict that positive regulators of these pathways
are critical for the survival of aneuploid cells, and thus
represent potential cancer therapeutic targets.
Overexpression of heat shock factor 1 (HSF1), the
master regulator of the proteotoxic stress response,
attenuates the negative effects of extra chromosomes on
protein folding [6]. This agrees with the established critical
role that HSF1 plays in tumour initiation [8] and in pro-
moting and maintaining cancer cell proliferation [8, 9].
High levels of HSF1 expression have been reported in a
number of cancers [10] and high levels of nuclear HSF1 are
associated with poor outcome in breast, hepatocellular and
endometrial carcinoma [11–13] among others. Under basal
conditions, HSF1 is maintained largely in the cytoplasm
and upon proteotoxic stress, HSF1 is activated and accu-
mulates in the nucleus [14]. Once in the nucleus, HSF1
activates a comprehensive transcriptional programme
including a number of genes encoding heat shock proteins
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(HSPs), which function as molecular chaperones and act to
protect cells against proteotoxic stress and apoptosis [15].
Of the HSPs, HSP70, is one of the best-characterised HSF1
targets, and is expressed at high levels in a variety of
cancers [16]. HSF1 activity and stability are tightly con-
trolled by multiple posttranslational modifications [17].
Among these, phosphorylation of serine 320 and serine 326
is associated with enhanced transcriptional activity,
stability and nuclear accumulation of HSF1 [18–20].
Importantly, the phosphorylation of S326 is both critical
and dominant over any inhibitory phosphorylation events
and is thus considered a hallmark of HSF1 activation [10].
Here we report that DYRK2 phosphorylates HSF1
increasing its nuclear stability and supporting its transcrip-
tional activity, and thus promoting resistance to proteotoxic
stress. We further show that in clinical TNBC samples
DYRK2 protein levels correlate with active HSF1, and are
associated with high rates of tumour recurrence and poorer
patient survival. Taken together, our data suggest that
DYRK2 is a hitherto unknown major regulator of the HSF1
pathway, which acts to promote TNBC cell survival. TNBC
is a tumour type characterised by genomic instability
and aneuploidy, high rate of recurrence and metastases,
for which current therapeutic options are limited [21].
Inhibition of DYRK2 may thus represent a novel approach
to compromise cellular proteostasis and increase the ther-
apeutic options for TNBC.
Results
DYRK2 phosphorylates HSF1
The dual specificity protein kinase YAK1, a member of
the DYRK family, phosphorylates and activates HSF1 in
Saccharomyces cerevisiae [22]. To test whether in a similar
way DYRK2 phosphorylates and activates HSF1 in human
cancer cells, we overexpressed DYRK2 and, by use of
phosphospecific antibodies, we observed that the levels of
endogenous HSF1 phosphorylated at S326 and S320 (two
main phosphorylation events linked to HSF1 activation)
were increased (Fig. 1A). The kinase activity of DYRK2
was required for the increased levels of pS326- and pS320-
HSF1, as a kinase-dead version of DYRK2 (DYRK2-KD)
did not induce HSF1 phosphorylation.
To further test the role of DYRK2 kinase activity on
HSF1 phosphorylation, we mutated the gatekeeper residue
within DYRK2, creating an analogue-sensitive DYRK2
form (DYRK2-AS) that is selectively sensitive to PP1
inhibitors [23]. Using the DYRK2-AS form together with
three different PP1 inhibitors, we observed that specific
inhibition of DYRK2 activity, dose-dependently reduced
the DYRK2-mediated phosphorylation of endogenous
HSF1 (Fig. 1B). In addition, harmine, a well-characterised
pan-specific DYRK inhibitor [24] (Fig. S1A) that inhibits
DYRK2 at concentrations in the µM range [25–28] also
reduced the phosphorylation of endogenous HSF1 mediated
by DYRK2 overexpression (Fig. S1B).
To address if HSF1 is a direct substrate for DYRK2, we
performed an in vitro kinase assay using recombinant His-
HSF1 and GST-DYRK2. We found that DYRK2-WT, but
not its kinase-dead version, phosphorylates His-HSF1 at
S326 and S320 in vitro (Fig. 1C). Furthermore, incubation
of recombinant GST-DYRK2-AS with a PP1 inhibitor
inhibited the phosphorylation of His-HSF1 on both S326
and S320, whereas as expected, the phosphorylation
mediated by GST-DYRK2-WT was not affected by the PP1
inhibitor (Fig. S1C). On the other hand, harmine inhibited
the phosphorylation of His-HSF1 mediated by both GST-
DYRK2-WT and GST-DYRK2-AS (Fig. S1D). Mass
spectrometry analysis of a sample taken at an early time
point (5 min) from the in vitro reaction showed that HSF1
was further phosphorylated at S307, T323 and S363
(Fig. S1E) although these sites could not be validated
in cells due to the lack of specific working antibodies.
Together, these results show that DYRK2 phosphorylates
HSF1 in cells and in vitro at S320 and also at S326, which
is critical for HSF1 activation.
Next, to test whether endogenous DYRK2 plays a role
in HSF1 activation by proteotoxic stress, we used the
prototypical HSF1 inducer heat shock (HS), in the
absence or in the presence of harmine, observing that the
inhibitor clearly impaired the phosphorylation of HSF1
upon HS (Fig S1F). Although in other cell lines three
other kinases (mTOR, MEK1 and p38) can phosphorylate
HSF1 at S326 [20, 29, 30], we have previously showed
that in TNBC cell lines, MEK1 does not regulate HSF1
[30]. To compare the relevance of mTOR and p38 with
that of DYRKs in the activation of HSF1 in response to
proteotoxic stress in TNBC, we compared the effect of the
DYRK inhibitor harmine, against the p38 inhibitor
SB202190 and the mTOR inhibitor rapamycin at impair-
ing HSF1 phosphorylation induced by HS. Our results
demonstrate that of the inhibitors and concentrations tes-
ted, the DYRK inhibitor harmine is the most effective in
impairing HSF1 phosphorylation (Figs. 1D and S1G) in
TNBC cells.
DYRK2 interacts with HSF1 via two domains
Our results provide evidence for a functional interaction
between DYRK2 and HSF1. In order to test whether
DYRK2 and HSF1 physically interact in cells, we per-
formed co-immunoprecipitation assays. The interaction
between the two proteins, which was not easily detectable
at basal conditions, was increased upon exposure to
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proteotoxic stress (Figs. 2A and S2A). This weak interac-
tion might reflect a transient binding between DYRK2 and
HSF1, which is a common occurrence for kinases and their
substrates. In order to map the interaction site(s), we used an
in vitro interaction peptide array. By incubating recombi-
nant GST-HSF1 with a membrane containing an array of
overlapping peptides covering the entire DYRK2 protein,
we identified two potential binding regions (Fig. 2B) within
conserved amino acid sequences (Fig. S2B). Binding region
1 (BR1) with sequence DDQGSYV, is located in a surface-
exposed loop, and binding region 2 (BR2) with sequence
TDA, falls within the unstructured C-terminus of DYRK2
(Fig. S2C). To validate the functional relevance of these
two regions, we created DYRK2 constructs harbouring
mutations either in BR1 or BR2, or in both simultaneously
(BR1+ 2). Based on our results, BR1 appeared to be more
important for the ability of DYRK2 to phosphorylate HSF1
(Fig. 2C). Furthermore, when both DYRK2 binding regions
were mutated, HSF1 phosphorylation was strongly reduced
on both S320 and S326, but notably, the ability of DYRK2
to phosphorylate SIAH2 [31], another known substrate,
remained intact (Fig. 2D). This observation suggests that
these two regions are not important for general DYRK2
kinase activity, but rather for its specific interaction with
Fig. 1 DYRK2 phosphorylates HSF1. A 293T cells were transiently
transfected to express GFP-tagged DYRK2 wild-type (WT) or a kinase
dead (KD) version. After 48 h, cells were lysed and the levels of
endogenous HSF1 and phospho-HSF1 were analysed as indicated.
B 293T cells were transiently transfected with a GFP-tagged DYRK2
analogue sensitive (AS) version. After 48 h, cells were treated for a
further 3 h with increasing concentrations of three different PP1
inhibitors as indicated. Cells were lysed and the levels of endogenous
HSF1 and phospho-HSF1 were analysed by western blot. C Upper
panel, purified recombinant His-HSF1 (1 µg) was incubated in kinase
buffer with increasing concentrations of recombinant GST-DYRK2 or
GST-DYRK2 kinase dead (KD) at 30 °C for 30 min. Lower panel,
purified recombinant His-HSF1 (1 µg) was incubated with either 20 ng
of GST-DYRK2 WT or KD at 30 °C for various times as indicated.
The reactions were terminated by the addition of SDS gel loading
buffer, the proteins were resolved by SDS-PAGE, and the levels of
phosphorylated HSF1 were analysed. D MDA-MB-468 cells were
treated with either DMSO, the p38 inhibitor SB202190 (10 µM), the
mTOR inhibitor rapamycin (30 nM) or harmine (10 µM). After 1 h,
cells were incubated at 42 °C. After 1 h, cells were lysed in SDS buffer
and the levels of the indicated proteins were analysed. Upper panel is a
representative western blot and the bottom panel shows the quantifi-
cation of the ratio between the phospho-HSF1 and total HSF1 levels.
Data represent means ± SD (n= 3) and are expressed relative to the
DMSO treated samples. See also Fig. S1.
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HSF1. In agreement, the DYRK2 BR1+ 2 mutant did not
interact with HSF1 (Fig. 2E).
DYRK2 promotes HSF1 nuclear stability
Phosphorylation of HSF1 is known to regulate its stability
[18, 20, 31]. Phosphorylation at Ser326 and S320 has been
involved in promoting HSF1 nuclear accumulation [18, 20],
and nuclear HSF1 is the active form. Therefore, we hypo-
thesise that DYRK2-mediated phosphorylation of those two
sites might increase HSF1 nuclear levels. To test this, we
first overexpressed DYRK2, and looked at the levels of
nuclear HSF1 at basal and after HS conditions (Fig. 3A and
Fig. S3A). Our results show that DYRK2 overexpression
promotes nuclear HSF1 accumulation. To further corrobo-
rate our findings, we used the opposite approach, employing
stable CRISPR-mediated knockout as well as siRNA-
mediated knockdown of DYRK2 to study the effect of
DYRK2 depletion on HSF1 nuclear levels. DYRK2
knockout cells showed an impaired HSF1 nuclear accu-
mulation in response to short exposure (5 min) to HS
(Figs. 3B and S3B). This impaired accumulation is less
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obvious at later time points (Fig. S3C, D). In addition, by
using a siRNA pool in combination with four individual
siRNAs against DYRK2 we showed that transient DYRK2
depletion also impaired the nuclear accumulation of HSF1
in response to short term HS (Figs. 3C and S3E). In our
experiments, we used two independent gRNAs to knockout
DYRK2 in two different TNBC cell lines (Fig. S3C and
S3D), obtaining in both cases, as with the siDYRK2, similar
results suggesting a specific effect. Nevertheless, to further
corroborate the on-target effect of DYRK2 on HSF1 nuclear
levels, we reconstituted TNBC DYRK2-KO cells with
either wild-type (WT) DYRK2 or the DYRK2 mutant
that cannot interact with HSF1 (BR1+ 2). As shown in
figures 3D and S3F, while WT DYRK2 recovers the sta-
bilisation of nuclear HSF1 in response to HS, the BR1+ 2
mutant does not.
To directly test whether the effect of DYRK on HSF1
nuclear accumulation depends on its phosphorylation at
S326 and S320, we compared the effect of DYRK2 on the
nuclear accumulation of either HSF1 WT or a HSF1
phospho-deficient mutant where both S326 and S320 were
mutated to alanine (S326A, S320A) (Figs. 3E and S3G).
Our results show that the phosphorylation-deficient mutant
shows an impaired accumulation in the nucleus in response
to DYRK2 overexpression, suggesting that those two sites
are important for the effect of DYRK2 on HSF1 nuclear
levels.
Although it has been shown that HSF1 nuclear stability is
regulated by the proteasome [32], HSF1 nuclear accumula-
tion in response to HS is still widely considered a con-
sequence of its nuclear translocation. However, in our
experiments, we noticed that HSF1 early nuclear accumula-
tion did not have associated any significant cytosolic reduc-
tion (Fig. S3H). We thus hypothesised that a reduction of
HSF1 nuclear degradation rather than nuclear translocation
was responsible for its early accumulation in response to HS.
To test whether the proteasome or the autophagosome-
lysosomal degradation pathways were involved, we used
drugs that inhibit those pathways. While bafilomycin A1
(autophagy/Lysosome inhibitor) did not affect HSF1 nuclear
levels (Fig. S3I), low doses of proteasome inhibitor MG132
were able to rapidly stabilise nuclear HSF1 without reducing
the cytosolic pool (Fig. S3J). Our results support the
hypothesis that the early accumulation of nuclear HSF1 in
response to HS depends on the proteasome, suggesting
that there is a nuclear pool of HSF1 that is constantly
being degraded and that in response to HS gets stabilised
(without involving nuclear transport).
Based on this, we tested whether the effect of DYRK2 on
nuclear HSF1 was affected by the presence of MG132. As
shown in figures 3F and S3K, MG132 recovers the levels of
nuclear HSF1 in DYRK2 depleted cells, suggesting that the
effect is in fact linked to the proteasome.
To directly assess the effect of DYRK2 on HSF1 nuclear
stability, we compared the HSF1 nuclear levels upon
cycloheximide treatment in control and DYRK2 knocked-
out TNBC cells. In cycloheximide chase experiments,
DYRK2 depleted cells had reduced levels of nuclear HSF1
with time, further suggesting that DYRK2 is involved in
HSF1 nuclear stability (Figs. 3G and S3L).
DYRK2 affects the expression levels of the HSF1
target gene HSP70
Based on its positive effect on the levels of nuclear (active)
HSF1, we hypothesised that DYRK2 could be promoting
HSF1 transcriptional activity. To test this hypothesis, we
compared the levels of the prototypic HSF1 target gene, HS
protein 70 (HSP70), in TNBC cells with and without
DYRK2. DYRK2 knockout reduced the inducible HSP70
mRNA and protein levels in response to HS (Figs. 4A–C
and S4A, B) and also to other proteotoxic stress inducers,
such as bortezomib (Fig. S4C); quantitative real-time PCR
revealed that in all cases, this reduction was by ~50%.
Similarly, and as expected, HSF1 knockout strongly
reduced the expression of HSP70, as well as its protein
levels (Figs. 4A, B and S4A, B). Importantly, the reduction
on both HSP70 expression and protein levels observed in
Fig. 2 DYRK2 interacts with HSF1 via two domains. A 293T cells
were transfected with the indicated plasmids. After 48 h, cells were
incubated at 42 °C for the indicated periods of time. A fraction of the
cell lysates was tested for the correct expression of the transfected
DYRK2 (Input), while the remaining extracts were used for immu-
noprecipitation with either anti-Flag antibodies or with the matched
IgG. After elution of bound proteins in 1X SDS sample buffer,
coprecipitated HSF1 was visualised by immunoblotting. B A peptide
array library covering the complete sequence of DYRK2 was incu-
bated with recombinant GST-HSF1 protein (upper panel) or a GST
control protein (lower panel) and the bound HSF1 protein was
revealed by immunoblotting against GST as shown. The specific
positive binding regions for HSF1 were indicated with a black box.
Sequences of DYRK2 peptides within the binding region 1 (BR1) or
binding region 2 (BR2) interacting with HSF1 are shown in bold.
C 293T cells were transiently transfected with the GFP-tagged ver-
sions of either DYRK2-WT or DYRK2 constructs harbouring muta-
tions on the BR1 or BR2 as indicated, or a DYRK2 YV/AR-T/A
mutant harbouring mutations in both regions (DYRK2 BR1+ 2).
After 48 h, cells were lysed and the levels of endogenous HSF1 and
phospho-HSF1 were analysed as indicated. D 293T cells were tran-
siently transfected with the Flag-tagged versions of either DYRK2-WT
or DYRK2 BR1+ 2, together with an inactive form of SIAH2 (HA-
SIAH2-RM). After 48 h, cells were lysed and the levels of the indi-
cated proteins were analysed as indicated. E 293T cells were trans-
fected with the indicated plasmids. After 48 h, cells were incubated at
42 °C for the indicated periods of time. A fraction of the cell lysates
was tested for the correct expression of the transfected proteins (input),
while the remaining extracts were used for immunoprecipitation with
anti-GFP antibodies. After elution of bound proteins in 1X SDS
sample buffer, coprecipitated HSF1 was visualised by immunoblotting
using an anti-Flag antibody as shown. See also Fig. S2.
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TNBC DYRK2-KO cells was recovered by reconstituting
them with the WT form of DYRK2, but not with the
DYRK2-HSF1 interaction deficient mutant (BR1+ 2)
(Figs. 4D, E and S4D).
DYRK2 reduces sensitivity to proteotoxic stress via
HSF1
Based on our data highlighting the importance of DYRK2
for HSF1 function in TNBC cells and on the well-
characterised protective role of HSF1 against proteotoxi-
city, we hypothesised that DYRK2 might protect TNBC
cells against proteotoxic stress. To assess the functional
significance of the reduced HSF1 activity in DYRK2-
impaired TNBC cells, we exposed cells to 45 °C (mild/
severe HS) which is a widely used stress to measure
thermo-tolerance, and as a proxy for HSF1 activity.
DYRK2 depletion sensitised TNBC cells to HS, as mea-
sured by cell viability (Fig. 5A) and by the levels of PARP
cleavage, a marker of apoptosis (Figs. 5B and S5A).
Importantly, the levels of apoptosis were reduced by
reconstituting the DYRK2 knockout cells with the WT form
of DYRK2, but not by reconstituting them with the
DYRK2-HSF1 interaction deficient mutant (BR1+ 2)
(Figs. 5C and S5B). In addition, the effect of DYRK2
knockdown on the enhanced sensitivity to proteotoxic stress
in WT cells (Figs. 5D and S5C) was largely abolished in
TNBC HSF1-KO cells (Figs. 5E and S5D), confirming the
importance of HSF1 for the cytoprotective role of DYRK2
in response to HS.
As DYRK2 has also been involved in the response to
DNA damage [33], we also tested the sensitivity of WT and
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DYRK2-KO TNBC cells to doxorubicin and paclitaxel
(Taxol), two chemotherapeutic drugs used in the clinic. As
shown in figure S5E, F, DYRK2-KO cells were not more
sensitive than the WT cells to these drugs, suggesting that
the previously observed increased sensitivity to HS is not a
general response to stress, but rather specific to proteotoxic
stress. In agreement, TNBC DYRK2-KO cells are also more
sensitive to the proteotoxic stress inducer Bortezomib [34].
DYRK2 levels correlate with HSF1 nuclear levels, and
associate with prognosis and tumour recurrence in
tissue from TNBC patients
The data so far show that DYRK2 regulates HSF1 nuclear
levels in TNBC cell lines. Next, as a first approximation to
address if DYRK2 regulates HSF1 in vivo, we asked
whether the levels of DYRK2 correlate with HSF1 levels in
tumour tissue from TNBC patients. To answer this question,
immunohistochemistry (IHC) was employed and the protein
levels of DYRK2 and HSF1 in both the cytoplasm and
nucleus were assessed separately (antibodies validation and
representative figures in figure S6A, B, C). In a cohort of
tissue samples from 102 TNBC patients, a weak correlation
was observed between cytoplasmic DYRK2 and cyto-
plasmic HSF1, and between nuclear DYRK2 and nuclear
HSF1 (Fig. S6D). The samples were then dichotomised into
high and low levels groups for DYRK2 and HSF1 in rela-
tion to a cut-off, determined using a receiver operating
characteristic (ROC) curve, with cancer death as an end-
point. Using this method, the cut-off was defined as 145 for
cytoplasmic DYRK2; 145 for nuclear DYRK2; 100 for
cytoplasmic HSF1; and 160 for nuclear HSF1. When ana-
lysed, no association by chi-square test was observed
between cytoplasmic DYRK2 and HSF1 (p= 0.385). By
contrast, a significant correlation was observed between
nuclear DYRK2 and nuclear HSF1 (p= 0.034) (Fig. 6A),
suggesting that high nuclear levels of DYRK2 correlate
with high nuclear HSF1 levels in triple-negative disease.
By interrogating publicly available datasets, we show
that, as recently reported [35], DYRK2 mRNA levels are
often higher in tumour than in normal tissue, correlating in
some cases with poor patient survival (Fig. S6E). We have
recently showed that DYRK2 protein levels are higher in
TNBC tumours than in adjacent normal tissue [36], how-
ever, the relationship between DYRK2 protein levels and
patient survival in different tumour types has not been
properly studied. Based on the observed novel correlation
between nuclear DYRK2 and nuclear HSF1 in TNBC
human samples and on the known association of nuclear
HSF1 with poor prognosis [10, 13], we hypothesised that
high levels of nuclear DYRK2 would also associate with
poor prognosis in TNBC. To test this hypothesis, we uti-
lised a cohort of 750 breast cancer samples that had avail-
able a previously constructed tissue microarray, including
148 TNBC (tissue microarrays (TMA) information in
Fig. S6F). Protein expression in both the tumour cell
cytoplasm and tumour cell nucleus was categorised as either
“low” or “high”, in relation to a cut-off as previously
indicated. DYRK2 protein levels were assessed in three
individuate TMA cores and mean weighted histoscore units
(WHU) employed for analysis (representative figures with
high and low DYRK2 levels in Fig. S6C). In the full cohort,
DYRK2 levels did not associate with survival (Fig. S6G).
However, in TNBC samples, high nuclear DYRK2 levels
significantly associated with reduced cancer-specific survi-
val (Fig. 6B) but not with overall survival (Fig. S6H).
Notably, the strength of this association was highest in the
TNBC subgroup of patients with ER, PR, HER2 and AR-
negative disease (Fig. 6C). In TN-AR-negative samples,
nuclear DYRK2 was observed as an independent factor in
Cox Regression multivariate analysis when combined with
other clinical parameters (Fig. S6I). Moreover, high nuclear
DYRK2 levels were associated with shorter time to
Fig. 3 DYRK2 promotes HSF1 nuclear stability. A 293T cells were
transfected with either empty vector or GFP-DYRK2. After 48 h, cells
were incubated at 37 or 42 °C for 5 min. Nuclear and cytoplasmic
fractions were analysed by western blot for the levels of the indicated
proteins. The corresponding quantifications of HSF1 protein levels are
shown in Supplementary Fig. S3A. B Control (WT) and CRISPR-
mediated DYRK2-KO MDA-MB-468 cells were incubated at 37 or at
42 °C for 5 min. Nuclear and cytoplasmic fractions were analysed by
western blot for the levels of the indicated proteins. The corresponding
quantifications of HSF1 protein levels are shown in Supplementary
Fig. S3B. CMDA-MB-468 cells were transfected with either siControl
or siDYRK2 (pool) or individual siDYRK2 (1–4). After 48 h, cells
were incubated at 37 or at 42 °C for 5 min. Nuclear fractions were
analysed by western blot for the levels of the indicated proteins. The
corresponding quantifications of HSF1 protein levels are shown in
Supplementary Fig. S3E. D DYRK2-KO MDA-MB-468 cells trans-
duced with virus encoding for either the empty vector (Ctrl), DYRK2-
WT (R. WT) or the DYRK2 HSF1-interaction deficient mutant
(R. BR1+ 2) were incubated at 37 or at 42 °C for 5 min. Nuclear
fractions were analysed by western blot for the levels of the indicated
proteins. The corresponding quantifications of HSF1 protein levels are
shown in Supplementary Fig. S3F. E 293T cells were transfected with
either Flag-tagged HSF1 or with Flag-tagged HSF1 mutant were S320
and S326 were mutated to alanine (S326AS320A) in combination with
either empty plasmid or GFP-DYRK2 as indicated. After 48 h, cells
were lysed and nuclear and cytosolic fractions were analysed for the
levels of the indicated proteins by western blotting. The corresponding
quantifications of HSF1 protein levels are shown in Supplementary
Fig. S3G. F Control (WT) and CRISPR-mediated DYRK2-KO MDA-
MB-468 cells were incubated with either DMSO or MG132 (10 µM).
After 1 h, cells were incubated at 37 or at 42 °C for 5 min. Nuclear and
cytoplasmic fractions were analysed by western blot for the levels of
the indicated proteins. The corresponding quantifications of HSF1
protein levels are shown in Supplementary Fig. S3K. G Control (WT)
and CRISPR-mediated DYRK2-KO MDA-MB-468 cells were incu-
bated with either DMSO (0) or Cycloheximide (10 µM) for the indi-
cated times. Nuclear fractions were analysed by western blot for the
levels of HSF1. The corresponding quantifications of HSF1 protein
levels are shown in Supplementary Fig. S3L. See also Fig. S3.
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recurrence in both TNBC and TN-AR-negative breast
cancer (Fig. 6D).
These results established DYRK2 as a potential prognostic
factor and promising novel therapeutic target in TNBC,
especially in the TN/AR-negative subgroup of patients, for
whom there is no targeted therapy available. Interestingly,
several of the commonly used TNBC cell models (including
the two cell lines used in this study, MDA-MB-231 and
MDA-MB-468) are also AR-negative [37].
Discussion
Cancer cells often rely on protein degradation and folding
pathways (i.e. proteasome, autophagy and HSF1 pathways)
to survive the high proteotoxic stress levels associated with
malignancy. The identification of new ways to target these
pathways, ideally simultaneously, might therefore provide
new and generalised therapeutic opportunities to target
cancer cells independently of their individual genetic
lesions responsible for cancer initiation. Indeed, the HSF1
pathway represents an attractive therapeutic target as it not
only allows cancer cells to survive aneuploidy-induced
proteotoxic stress, but it also plays an important role in
cancer progression and chemoresistance [8, 10, 13, 38, 39].
However, developing specific HSF1 inhibitors has proven
to be challenging, and thus, an alternative approach is to
understand and to target HSF1 upstream regulatory path-
ways. In this study, we shed light on the regulation of the
HSF1 pathway by the kinase DYRK2. We propose that
DYRK2 regulates HSF1 nuclear levels and it is the main
kinase regulating HSF1 activation in TNBC, and the first
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kinase described to phosphorylate HSF1 at both S326 and
S320 sites. Remarkably, DYRK2 depletion is sufficient
to impair HSF1 nuclear levels and HSP70 expression,
increasing TNBC cell sensitivity towards proteotoxic stress.
This suggests that although other kinases might also reg-
ulate HSF1 activity, they cannot completely compensate for
the absence of DYRK2.
Our data show that DYRK2 activates the pro-survival
HSF1 pathway providing a support mechanism and a sur-
vival advantage to cancer cells. Importantly, this new link
between DYRK2 and HSF1 appears to be relevant in TNBC
patients as DYRK2 levels correlate positively with HSF1
nuclear levels, and negatively associate with cancer-specific
survival and time to recurrence, supporting a pro-tumoural
role for DYRK2 in TNBC. Furthermore, our data suggest
that nuclear DYRK2 might be the pool responsible for its
HSF1-dependent tumour promoter role in TNBC.
Although it has been suggested that DYRK2 might have
both a “tumour suppressor” and a “tumour promoter” role
[34, 40–44], our data support the hypothesis that in TNBC
DYRK2 acts as a “tumour promoter”. Furthermore, our
results suggest that DYRK2 may be both a prognostic
biomarker and a potential therapeutic target, which will be
especially relevant in TN-AR-negative breast cancer
patients, for whom there is no targeted therapy available.
The development of new specific DYRK2 inhibitors and
their validation in vivo (i.e. using xenograft and genetic
models) is needed to further substantiate this hypothesis. In
this context, it is encouraging to see the results from two
recent studies showing that treatment with the DYRK2
inhibitors curcumin and LDN192960 impaired growth of
established TNBC tumours [36, 40]
Our data, together with previous reports showing that
DYRK2 controls proteasome activity [34], presents DYRK2
as a major apical positive regulator of two main pathways
involved in alleviation of proteotoxic stress in cancer cells,
and thus two main mechanisms by which aneuploid cells
adapt, survive and become malignant. Thus, DYRK2 inhibi-
tion, by impairing both supporting mechanisms, might be an
excellent way to tackle not only TNBC cells, but also other
aneuploid cancer cells that depend on such support mechan-
isms, independently on their genetic background.
Material and methods
Cell culture
MDA-MB-231 were obtained from the culture collection at
Public Health England. 293T and MDA-MB-468 cell lines
were obtained from ATCC. All cell lines were grown in
DMEM containing 10% FBS at 37 °C and 5% CO2. Cells
were routinely tested for mycoplasma and those that were
not recently bought, were authenticated by SRT profile
before submission. Cells are passaged once 70–90% con-
fluency is reached, and are maintained in culture for no
more than 20 passages. Freshly thawed cells are passaged
2–3 times before used.
Antibodies, plasmids and reagents
Antibodies recognising Flag (F1804) were obtained from
Sigma-Aldrich (Dorset, UK); anti-HA (sc-805), anti-Lamin
B2 (sc-56147) and anti-Tubulin (sc-8035) were obtained from
Santa Cruz Biotechnology (Dallas, Texas, USA). Anti-GFP
anti-DYRK2 were obtained from the MRC Protein Phos-
phorylation and Ubiquitination Unit, (School of Life Science,
University of Dundee, UK); anti-cleaved PARP (9546S)
and anti-DYRK2 (8143) were obtained from Cell Signalling
(MA, USA); anti-HSF1 (ADI-SPA-901-D) was obtained
from Enzo Life Science (NY, USA); anti-phospho-HSF1-Ser
326 (ab115702), anti-phospo-HSF1-Ser 320 (ab76183) and
anti-GST-HRP (ab3416) were obtained from Abcam (Cam-
bridge, UK). HRP-conjugated secondary antibodies (31430
and 31460) and Dynabeads™ Protein G (10004D) were
obtained from Life Technologies (Carlsbad, California, USA).
Expression vectors for DYRK2-GFP, DYRK2-KD-
GFP, DYRK2-Flag and SIAH2-RM-HA were a gift from
Fig. 4 DYRK2 affects the expression levels of the HSF1 target gene
HSP70. A Control (WT), DYRK2-KO or HSF1-KO MDA-MB-468
cells were incubated at 37 or 42 °C for 1 h. The mRNA levels for
HSP70 (HSPA1A) were quantified using real-time PCR. The data were
normalised using β-actin as an internal control. Data represent means
± SD (n= 3) and are expressed relative to the control sample levels at
37 °C. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, B Control (WT), DYRK2-
KO or HSF1-KO MDA-MB-468 cells were incubated at 37 or at 42 °C
for 1 h followed by another hour at 37 °C. Cells were lysed and the
levels of the indicated proteins were analysed by western blot. The
corresponding quantifications of HSP70 protein levels are shown in
Supplementary Fig. S4B. C Control (WT) and DYRK2-KO MDA-
MB-468 cells were incubated at 37 °C, at 42 °C for 5, 15, 30 or 60
min, or at 42 °C for 60 min plus recovery time at 37 °C (up to 180
min). After that, mRNA levels for HSP70 (HSPA1A) were quantified
using real-time PCR. The data were normalised using β-actin as an
internal control. Data represent means ± SD (n= 3) and are expressed
relative to the control samples at 37 °C. D DYRK2-KO MDA-MB-468
infected with virus encoding for either empty vector (Ctrl), DYRK2-
WT (R. WT) or the DYRK2 HSF1-interaction deficient mutant
(R. BR1+ 2) were incubated at 37 °C or at 42 °C for 60 min. After
that, mRNA levels for HSP70 (HSPA1A) were quantified using real-
time PCR. The data were normalised using β-actin as an internal
control. Data represent means ± SD (n= 3) and are expressed relative
to the control samples at 37 °C. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
E DYRK2-KO MDA-MB-468 infected with virus encoding for either
empty vector (Ctrl), DYRK2-WT (R. WT) or the DYRK2 HSF1-
interaction deficient mutant (R. BR1+ 2) were incubated at 37 °C or at
42 °C for either 60 or 120 min. Cells were lysed and the levels of the
indicated proteins were analysed by western blot. The corresponding
quantifications of HSP70 protein levels are shown in Supplementary
Fig. S4D. See also Fig. S4.
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Marco A. Calzado (University of Cordoba, Spain); HSF1-
GFP have been already described [30]. All gRNAS were
cloned into pLentiCRISPr-V2, which was a gift from
Feng Zhang (Addgene plasmid #52961). Point mutants
were produced by conventional point mutagenesis. The
DYRK2-analogue sensitive was obtained by mutating
the gatekeeper residue F228 to Alanine. His-HSF1 has
already been described [30] and GST-DYRK2 was
obtained from the MRC Protein Phosphorylation and
Ubiquitination Unit (School of Life Science, University of
Dundee, UK). DYRK2-WT and DYRK2-BR1+ 2 were
cloned into the lentiviral 290-puro plasmid [45] obtaining
a puro resistant construct that was used for reconstitution
experiments.
Fig. 5 DYRK2 reduces sensitivity to proteotoxic stress via HSF1.
A Equal number of MDA-MB-468 WT (Left panel) or DYRK2-KO
(Right panel) were seeded. After 24 h, cells were exposed to 45 °C
(HS) for 45 min followed by recovery at 37 °C (cells labelled as 45 °C)
or they were left at 37 °C (cells labelled as 37 °C). Number of cells at
each point were analysed using the Alamar Blue assay. Data represent
means ± SD (n= 3). B Control (WT) and DYRK2-KO MDA-MB-468
cells were incubated at 37 °C (−) or at 45 °C for the indicated times,
followed by recovery at 37 °C. On the next day, cells were lysed and
the levels of apoptosis were analysed by western blotting using an
antibody that recognises cleaved PARP. The corresponding quantifi-
cations of PARP protein levels are shown in Supplementary Fig. S5A.
C DYRK2-KO MDA-MB-468 infected with virus encoding for either
empty vector (Ctrl), DYRK2-WT (R. WT) or the DYRK2 HSF1-
interaction deficient mutant (R. BR1+ 2) were incubated at 37 °C or at
45 °C for 45 min followed by recovery at 37 °C. On the next day, cells
were lysed and the levels of apoptosis were analysed by western
blotting using an antibody that recognises cleaved PARP. The corre-
sponding quantifications of PARP protein levels are shown in Sup-
plementary Fig. S5B. MDA-MB-468 (D) or HSF1-KO MDA-MB-468
(E) cells transfected with either siControl or siDYRK2 were incubated
at 37 °C or at 45 °C for the indicated times, followed by recovery at
37 °C. On the next day, cells were lysed and the levels of apoptosis
were analysed by western blotting using an antibody that recognises
cleaved parp. The corresponding quantifications of PARP protein
levels are shown in Supplementary Fig. S5C, D. See also Fig. S5.
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The siRNAs used against DYRK2 were the SMART
pool: ON-Target Plus, and its four individual siRNAs all
from Dharmacon (CO, USA).
Bortezomib (sc-217785) was obtained from Santa Cruz
Biotechnology. Harmine (5075) was obtained from Tocris
Bioscience (Bristol, UK), PP1 inhibitors (17860, 10954 and
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13330) were obtained from Cayman Chemicals (MI, USA).
The p38 inhibitor SB202190 (1073) was obtained from
SYNkinase (3052, Australia) and the mTOR inhibitor
Rapamycin (553210) was obtained from Sigma-Aldrich.
Quantitative real-time PCR (rt-qPCR)
RNA was extracted using RNeasy kit (QIAGEN). Overall,
500 ng of RNA per sample was reverse-transcribed to cDNA
using Omniscript RT kit (QIAGEN) supplemented with
RNase inhibitor (QIAGEN) according to the manufacturer’s
instructions. Resulting cDNA was analysed using TaqMan
Universal Master Mix II (Life technologies). Gene expression
was determined using an Applied Biosystems 7300 Real-
Time PCR system by the comparative ΔΔCT method. All
experiments were performed at least in triplicates and data
were normalised to the housekeeping gene β-actin. Probes
were obtained from Applied Biosystems. When applicable,
the differences between groups were determined by two-way
ANOVA. Analyses were performed using GraphPad Prism
(GraphPad Software); a P value of <0.05 was considered
significant. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
Cell transfections
On the day prior to transfection, cells were plated to the
required cell density (70–90% confluency). Lipofectamine
2000 and Lipofectamine RNAiMAX (Invitrogen) were used
for plasmid DNA and siRNA, respectively. The plasmid
DNA/siRNA and lipofectamine were individually diluted in
Optimem (Gibco) and incubated for 10min at room tem-
perature. Diluted DNA/siRNA was added to the diluted
Lipofectamine solution (1:1 ratio) and further incubated for
15 min. DNA-lipid complex was added to the cells and
incubated overnight in a humidified incubator at 37 °C and
5% CO2. The next morning, the medium was replaced with
fresh medium and cells were incubated 36 h more prior lysis.
Cell viability assays
Equal number of the different cell lines were seeded. After
treatment (either HS or chemotherapeutic drugs) the number
of metabolically active cells were measured using the Ala-
mar Blue assay (Thermo Fisher Scientific) following the
manufacturer’s instructions.
Lentivirus production and cell transduction
293T cells were transfected using Lipofectamine 2000
(Invitrogen) with the empty vector (290-pHAGE-hEF1a
CAR-PGK Puro) or the lentiviral DYRK2-WT, or DYRK2
mutant (BR1+ 2) together with the packaging vectors
(pMDLg/pRRE, pRSV-Rev and pHCMVG) and cultivated
in OptiMEM medium (Invitrogen). The next day the cells
were further grown in DMEM complete medium and 1 day
later the lentivirus-containing supernatant was collected,
filtered and used to transduce cells.
Cells were incubated with the media-containing virus
complemented with Polybrene (8 μg/ml) for 16 h, followed
by a medium exchange. Transduced cells were selected by
further growth in the presence of 2 μg/ml puromycin; the
surviving cells were tested by immunoblotting for adequate
DYRK2 expression.
Cell lysis protocol and western blotting
Cells were washed and harvested in ice-cold phosphate-
buffered saline (PBS) and lysed in either SDS buffer
or RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl,
2 mM EDTA, 1% NP40, 0.5% sodium deoxycholate,
0.5 mM Na3VO4, 50 mM NaF, 2 μg/ml leupeptin, 2 μg/ml
aprotinin, 0.05 mM pefabloc). Cells directly lysed in SDS
were boiled for 2 min, sonicated and boiled again for
another 5 min. Cells lysed in RIPA buffer were sonicated
and lysates were cleared by centrifugation for 15 min at
4 °C. Protein concentration was established using the BCA
assay (Pierce). Supernatant was mixed with SDS sample
buffer and boiled for 5 min. Equal amounts of protein
were separated by SDS-PAGE, followed by semidry blot-
ting to a polyvinylidene difluoride membrane (Thermo
Scientific). After blocking of the membrane with 5% (w/v)
TBST non-fat dry milk, primary antibodies were
added. Appropriate secondary antibodies coupled to
horseradish peroxidase were detected by enhanced chemi-




Cells were washed and harvested with ice-cold PBS.
Pelleted cells were resuspended in 400 μl of low-salt
buffer A (10 mM Hepes/KOH pH 7.9, 10 mM KCL,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM β-Mercaptoetha-
nol). After incubation for 10 min on ice, 10 μl of 10%
Fig. 6 DYRK2 levels correlate with HSF1 nuclear levels and
associates with poor prognosis and tumour recurrence in tissue
from TNBC patients. A Chi-Square test correlations between nuclear/
cytoplasmic HSF1, and nuclear/cytoplasmic DYRK2 in triple-negative
breast cancer. Relationship between either cytoplasmic DYRK2 levels
(left panel) or nuclear DYRK2 levels (right panel) and cancer-specific
survival in (B) patients with triple-negative invasive ductal breast
cancer, and (C) patients with triple-negative and AR-negative invasive
ductal breast cancer. D Relationship between nuclear DYRK2 levels in
tumour cells and time to recurrence in patients with triple negative (left
panel) or triple negative and AR-negative (right panel) invasive ductal
breast cancer. See also Fig. S6.
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NP-40 was added and cells were lysed by gently vortex-
ing. The homogenate was centrifuged for 10 s at 13,200
rpm in a microfuge. The supernatant representing the
cytoplasmic fraction was collected and the pellet con-
taining the cell nuclei was washed 4 additional times in
buffer A, then resuspended in 100 μl high-salt buffer B
(20 mM Hepes/KOH pH 7.9, 400 mM NaCL, 1 mM
EDTA, 1 mM EGTA, 1 mM β-Mercaptoethanol). The
lysates were sonicated and centrifuged at 4 °C for 15 min
at 13,200 rpm. The supernatant representing the nuclear
fraction was collected. Protease and phosphatase inhibi-
tors were freshly added to both buffers.
Immunoprecipitation
Cells were washed with PBS and lysed in IP buffer (50 mM
Hepes pH 7.5, 50 mM NaCl, 1% (v/v) Triton X-100, 2 mM
EDTA, 10 mM sodium fluoride, 0.5 mM sodium orthova-
nadate, leupeptin (10 µg/ml), aprotinin (10 µg/ml), and
1 mM PMSF), followed by a sonication step. The extract
was centrifuged and the supernatant was transferred to a
new tube. The immunoprecipitation was performed with
2 μg of precipitating antibodies together with 50 µl of
Dynabeads™ Protein G. Tubes were rotated for 30 min on a
spinning wheel at 4 °C. The immunoprecipitates were
washed 3x with PBS/0,01% Tween-20 and eluted by boil-
ing in 1X SDS sample buffer. Equal amounts of protein
were separated by SDS-PAGE.
CRISPR-edited cell lines
The endogenous DYRK2 or HSF1 genes were knocked out
by transfecting cells with pLentiCRISPR-v2 (which codes
for Cas9, and a puromycin cassette) containing gRNAs
against the first exon of the short DYRK2 isoform or against
the fourth exon of HSF1. For MDA-MB-231 cells the
gRNA sequence used was GCTTGCCAGTGGTGCCA
GAG and for MDA-MB-468 DYRK2-KO cells the target
sequence was CGCTCACGGACAGATCCAGG. In addi-
tion, we also tested some of our results in MDA-MB-231
cells in which we almost completely remove the
DYRK2 ORF by using two gRNAs (N-term sequence
GCTTGCCAGTGGTGCCAGAG and C-term sequence
GAAGCTGAGCTAGAAGGTGG). For HSF1-KO cells
the gRNA sequence used was AAGTACTTCAAGCA-
CAACAA. Control cells were transfected with the empty
pLentiCRISPRV2 vector. After transfection, cells were
exposed to 2 μg/ml of puromycin for 2 days followed by a
medium exchange. Surviving cells were clonally selected
(in the case of control cells were used as pool population)
by serial dilution, and positive clones were identified by
genomic analysis and western blot. At least two clones for
each cell line were used for the experiments.
In vitro kinase assay
Bacterially expressed full length HSF1 His tagged was
incubated with GST-DYRK2 in Kinase Buffer (25 mM
TRIS pH 7.5, 5 mM β-glycerophosphate, 10 mM MgCl2
and freshly added 2 mM DTT, 0.1 mM Na3VO4, 1 mM
ATP) for different periods of time (5–60 min) at 30 °C. The
reaction was inactivated by adding SDS loading buffer (50
mM Tris-HCl pH 6.8, 10%, SDS, 40% glycerin, 15% β-
mercaptoethanol, 0.1% bromophenol blue) and samples
were boiled at 95 °C for 5 min and loaded in SDS-
PAGE gels.
In vitro peptide binding
Overlapping dodecapeptides covering the entire DYRK2
protein were spotted in an automated process on cellulose
membranes by using Fmoc-protection chemistry (Pro-
teomics facility, CNB-CSIC, Spain). The membrane was
blocked overnight in non-fat milk in TBS buffer and incu-
bated for 6 h with 60 nmol of recombinant GST-HSF1 or
GST proteins as a control. After extensive washing, anti-
GST antibody coupled to horseradish peroxidase was added
for 1 h. After washing, blots were revealed by enhanced
chemiluminescence using Clarity™ Western ECL Blotting
Substrate (BIO-Rad).
Mass spectrometry
Purified His-HSF1 (1 ug) was incubated with GST-DYRK2
(20 ng) in 20 uL buffer containing 25 mM Tris-HCl (pH
7.5), 5 mM MgCl2, and 1 mM ATP for 5 min. The mixtures
were reduced, alkylated and digested with trypsin (1:100)
prepared in 100 mM TEAB buffer (pH 8.5). The mixture
was incubated at 37 °C overnight before 8 uL of 10 mM
EDTA (in 0.1% TFA) was added. The peptide mixture was
then subjected to nano-LC-MS/MS analysis according to a
previous report [46]. Database search was carried out using
Peaks 7.0 against UniProt-human (version 2018-05-28).
False discovery rate was set at 1% (for peptide spectrum
matches). The non-modified and modified (methionine
oxidation and phosphorylation) peptides from HSF1
detected are shown in blue lines. The putative oxidation
sites are labelled in yellow and phosphorylation sites in red.
Patient cohort and tissue microarrays
Patients presenting with invasive ductal breast cancer at
Glasgow Royal Infirmary, Western Infirmary and Stobhill
Hospital between 1995 and 1998, with formalin-fixed par-
affin-embedded blocks of the primary tumour available for
evaluation were studied (n= 850). The study was approved
by the Research Ethics Committee of the West Glasgow
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University Hospitals NHS Trust with consent obtained from
all subjects. Clinicopathological data including age, tumour
size, tumour grade, lymph node status, type of surgery and
use of adjuvant treatment (chemotherapy, hormonal based
therapy and/ or radiotherapy) were retrieved from the rou-
tine reports. Tumour grade was assigned according to the
Nottingham Grading System. ER and PR status were
assessed on TMAs using IHC with Dako (Glostrup, Den-
mark) ER antibody and Leica (Wetzlar, Germany) PR
antibody. Her2 status was assessed as described [47].
Tissue analysis
IHC was conducted in triplicate on TMAs. Prior to this,
antibody specificity was confirmed using proficient and
deficient cell lines (either knockdown or knockout cell
lines) (Fig. S6A). TMA sections (2.5 µm) were dewaxed by
immersion in histoclear then rehydrated using a series of
alcohols. Heat-induced antigen retrieval was performed in a
solution of either Tris-EDTA pH9 (DYRK2) or citrate
buffer pH 6 (HSF1) after which the sections were incubated
in 3% hydrogen peroxide. Non-specific binding was
blocked by incubation in 1.5% normal horse serum before
being incubated with the optimum concentration of primary
antibody overnight at 4 °C. Antibody dilutions were
prepared in antibody diluent (Agilent, London, UK). The
primary antibodies and concentrations used are as follows;
DYRK2 (Abgent AP7534a) at 1:200 and HSF1 (Cell Sig-
nalling 4256) at 1:500. Staining was visualised using
ImmPRESSTM and ImmPACTTM DAB, (both Vector Labs).
Tissue was counterstained using Harris Haematoxylin
before being dehydrated and mounted using DPX.
The stained TMA sections were scanned using a
Hamamatsu NanoZoomer (Welwyn Garden City, Hert-
fordshire, UK) at ×20 magnification. Visualisation was
carried out using Slidepath Digital Image Hub, version 4.0.1
(Slidepath, Leica Biosystems, Milton Keynes, UK). Protein
expression was performed at a magnification of ×400,
expression in cytoplasmic and nuclear compartments was
assessed separately using the Weighted Histoscore Tech-
nique as previously described [48]. The weighted histoscore
is performed by assessing the percentage cells with no
staining (0), percentage of cells with weak staining (1),
percentage of cells with moderate staining (2), and per-
centage of cells with strong staining (3) for each of the
cellular locations. This was then entered into the below
formula to provide a score from 0 to 300.
Total score = (% of unstained tumor cells × 0) +
(% of weakly stained tumor cells × 1) + (% of moder-
ately stained tumor cells × 2) + (% of strongly stained
tumor cells × 3)
Where a total score of 0 means tumour tissue is negative
for protein expression at that cellular location, and a total
score of 300 means tumour tissue strongly expressed pro-
tein at that cellular location.
Since each patient was represented by three different
cores on the TMA, this was repeated for each core, and
mean of these was calculated to provide the score used in
the analysis. The weighted histoscore method was
employed to assess protein expression (GB), with a second
independent observer (JE) scoring 10% of the scores. The
results were considered discordant if the histoscores differed
by more than 50 WHU.
Protein expression in both the tumour cell cytoplasm and
tumour cell nucleus was categorised as either “low” or
“high”, in relation to a cut-off. This cut-off was determined
using a ROC curve based on survival, with cancer death as
an endpoint.
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